Quinsam Reports Q1/2025 Results

Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Quinsam Capital Corporation (CSE: QCA) ("Quinsam" or the "Company") is announcing its Q1/2025 results, with net income of $0.2 million ($0.00 per share basic, $0.00 fully diluted) versus net income of $0.5 million ($0.00 per share basic, $0.00 fully diluted) in Q1/2024. Investors can access the Company's full financial statements on sedarplus.ca.

"On the whole the movements in the values of our investments in Q1/2025 were relatively modest. The share price of Blumetric increased nicely from year-end and has continued to perform well in Q2 to date. We note that we exited our final US cannabis-related investment (some convertible debentures in CLS Holdings)," said Roger Dent, CEO.

In Quinsam's private securities portfolio, a number of liquidity events are pending. Reeflex Coil Solutions has closed its RTO with Bigstack Opportunities I and should trade in the coming days. Peninsula (the US single family rental business) is making efforts to list in the coming months. Exiteam (operating as VVT Medical) is in the final stages of completing its RTO and expects to trade this quarter. Theracann, which we fully wrote off some years ago, is now nearing a listing as Beyond Farming through a merger with Sprout AI on the CSE. Electro Metals has announced its intent to list through a merger with BWR Exploration.

"At March 31, 2025, we had net assets of approximately $0.10 per share outstanding," said Roger Dent, CEO. "Our shares continue to trade at a very steep discount from NAV. We also note that the total of our more liquid investments (including cash, public equities, and derivatives on public equities) is approximately $0.05 per share."

Quinsam made a new investment in Pelican AI in Q1, which is expected to list in the near term.

The search for a value creating transaction continues. We anticipate that it may take some time to find a suitable, value creating transaction. There have been relatively few companies undertaking new listings and our plan is to patiently wait for a high quality transaction. Further announcements will be made on the status of such steps which are subject to all applicable shareholder and regulatory approvals.

Issuer Bid

In Q1/2025, the Company acquired no shares pursuant to its issuer bid to purchase up to 4,600,000 of its common shares that commenced on September 6, 2024 and will terminate on September 5, 2025, or on an earlier date in the event that the number of common shares sought in the bid has been repurchased. Total purchases pursuant to this bid are 2,955,000 shares.